<DOC>
	<DOCNO>NCT01491113</DOCNO>
	<brief_summary>This human pharmacology , single-dose study investigate pharmacokinetics orally administer Levetiracetam ( LEV ) Japanese subject normal renal function Japanese subject various degree impair renal function .</brief_summary>
	<brief_title>Pharmacokinetic ( PK ) Study Japanese Non-epileptic Renal Impaired Patients</brief_title>
	<detailed_description>The primary objective study evaluate plasma urine PK Levetiracetam ( ucb L059 ) metabolite ( ucb L057 ) single dose LEV 250 mg LEV 500 mg Japanese subject normal renal function Japanese subject various degree renal impairment .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Healthy subject normal renal function Subject Japanese Subjects creatinine clearance within 1 3 Groups ( CLcr [ mL/min/1.73 cm^2 ] : Group B : 50 &lt; 80 , Group C : 30 &lt; 50 , Group D : &lt; 30 ) , Group E , subject endstage renal failure undergo hemodialysis Subjects take drug treatment , disease injury influence Levetiracetam PK except renal impairment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Oral administration</keyword>
	<keyword>Japanese</keyword>
	<keyword>Non-epileptic</keyword>
	<keyword>Healthy</keyword>
	<keyword>Renal impaired subject</keyword>
</DOC>